EP3768264A4 - AROMATIC ALDEHYDE WITH DELAYED AND IMPROVED PHARMACOLOGICAL IN-VITRO AND IN-VIVO ACTIVITY FOR TREATMENT OF SICKLE CELL DISEASE - Google Patents

AROMATIC ALDEHYDE WITH DELAYED AND IMPROVED PHARMACOLOGICAL IN-VITRO AND IN-VIVO ACTIVITY FOR TREATMENT OF SICKLE CELL DISEASE Download PDF

Info

Publication number
EP3768264A4
EP3768264A4 EP19772630.0A EP19772630A EP3768264A4 EP 3768264 A4 EP3768264 A4 EP 3768264A4 EP 19772630 A EP19772630 A EP 19772630A EP 3768264 A4 EP3768264 A4 EP 3768264A4
Authority
EP
European Patent Office
Prior art keywords
vitro
delayed
treatment
sickle cell
cell disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19772630.0A
Other languages
German (de)
French (fr)
Other versions
EP3768264A1 (en
Inventor
Martin K. Safo
Yan Zhang
Piyusha Pradeep PARAGE
Guoyan XU
Mohini GHATGE
Jurgen VENITZ
Osheiza ABDULMALIK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Childrens Hospital of Philadelphia CHOP
Original Assignee
Virginia Commonwealth University
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University, Childrens Hospital of Philadelphia CHOP filed Critical Virginia Commonwealth University
Publication of EP3768264A1 publication Critical patent/EP3768264A1/en
Publication of EP3768264A4 publication Critical patent/EP3768264A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19772630.0A 2018-03-22 2019-03-18 AROMATIC ALDEHYDE WITH DELAYED AND IMPROVED PHARMACOLOGICAL IN-VITRO AND IN-VIVO ACTIVITY FOR TREATMENT OF SICKLE CELL DISEASE Withdrawn EP3768264A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862646434P 2018-03-22 2018-03-22
PCT/US2019/022678 WO2019182938A1 (en) 2018-03-22 2019-03-18 Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell disease

Publications (2)

Publication Number Publication Date
EP3768264A1 EP3768264A1 (en) 2021-01-27
EP3768264A4 true EP3768264A4 (en) 2021-12-22

Family

ID=67987977

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19772630.0A Withdrawn EP3768264A4 (en) 2018-03-22 2019-03-18 AROMATIC ALDEHYDE WITH DELAYED AND IMPROVED PHARMACOLOGICAL IN-VITRO AND IN-VIVO ACTIVITY FOR TREATMENT OF SICKLE CELL DISEASE

Country Status (3)

Country Link
US (2) US11401241B2 (en)
EP (1) EP3768264A4 (en)
WO (1) WO2019182938A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120584098A (en) * 2022-11-07 2025-09-02 弗吉尼亚联邦大学 Benzaldehyde compounds with direct polymer-destabilizing effects for the treatment of sickle cell disease
WO2025003974A1 (en) 2023-06-30 2025-01-02 Chong Kun Dang Pharmaceutical Corp. New preparation method of compound and new crystalline form

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410537A (en) * 1979-06-29 1983-10-18 Burroughts Wellcome Co. Pharmaceutical ethers
WO2013102142A1 (en) * 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2015027067A2 (en) * 2013-08-23 2015-02-26 Virginia Commonwealth University Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2893663A1 (en) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Phenylethylpyridine derivatives as pde4-inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410537A (en) * 1979-06-29 1983-10-18 Burroughts Wellcome Co. Pharmaceutical ethers
WO2013102142A1 (en) * 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2015027067A2 (en) * 2013-08-23 2015-02-26 Virginia Commonwealth University Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NNAMANI I N ET AL: "Pyridyl derivatives of benzaldehyde as potential antisickling agents", CHEMISTRY & BIODIVERSITY, HELVETICA CHIMICA ACTA, ZUERICH, CH, vol. 5, no. 9, 1 September 2008 (2008-09-01), pages 1762 - 1769, XP002732217, ISSN: 1612-1872, [retrieved on 20080924], DOI: 10.1002/CBDV.200890165 *
See also references of WO2019182938A1 *

Also Published As

Publication number Publication date
EP3768264A1 (en) 2021-01-27
US11401241B2 (en) 2022-08-02
US20220340531A1 (en) 2022-10-27
WO2019182938A1 (en) 2019-09-26
US20210002225A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
PL3673080T3 (en) Antisense oligomers for the treatment of conditions and diseases
EP3931189C0 (en) AZEPINO-INDOLE AND OTHER HETEROCYCLENS FOR THE TREATMENT OF BRAIN DISEASES
IL268850A (en) Combinations of 4-pyrimidinesulfamide derivatives with active ingredients for the treatment of endothelin-related diseases
IL276383B1 (en) Treatment of ophthalmologic diseases
EP3919049C0 (en) COMBINATIONS OF RAPAMYCIN AND METFORMIN FOR THE TREATMENT OF JOINT AND SKIN DISEASES
EP3723513C0 (en) PROBIOTICS AND FERMENTATION METABOLITES FOR THE PREVENTION AND TREATMENT OF DISEASE CONDITIONS IN ANIMALS
EP3880304C0 (en) COMPOSITIONS FOR THE TREATMENT OF OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES AND SKIN AGING
EP3737692A4 (en) CALRETICULIN-BINDING CONSTRUCTS AND GENERALLY MODIFIED T-CELLS FOR THE TREATMENT OF DISEASES
EP3760107C0 (en) SYSTEM FOR THE EXAMINATION AND MONITORING OF HEART DISEASES
EP3565549A4 (en) SELECTIVE HISTONE ACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASES
EP3959213C0 (en) PYRIMIDINE-JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES
EP3768386A4 (en) GENE THERAPEUTICS FOR THE TREATMENT OF BONE DISEASES
EP3583113A4 (en) USE OF TGF-ALPHA FOR TREATMENT OF DISEASES AND DISORDERS
EP3716972A4 (en) PYRANOPYRAZOLES AND PYRAZOLOPYRIDINE IMMUNODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
IL269083A (en) Methods for the prevention and treatment of heart diseases
EP3903796C0 (en) Pharmaceutical composition and manufacturing process thereof and use thereof for the treatment of heart failure
EP3801626A4 (en) USE OF RILUZOL ORAL DISINFECTANT TABLETS TO TREAT DISEASES
HUE064761T2 (en) Treatment of patients with classic fabry disease with migalastat
EP3740282C0 (en) METALLOTHIONEINE INHIBITORS FOR THE TREATMENT OF DIABETES, HEPATITIS AND/OR INFLAMMATORY LIVER DISEASE
EP2411004A4 (en) USE OF ANDROGRAPHOLIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASE AND RESPIRATORY DISEASES
EP3960858C0 (en) Small RNA drug for the prevention and treatment of inflammation-related diseases and combinations thereof
IL290712A (en) Management of non-MS conditions in patients treated with ofatumumab
EP4447985A4 (en) Spray-dried inhalable biotherapeutics for the treatment of diseases
EP3723745C0 (en) PHENOXY ACID FOR THE TREATMENT OF NEUROMUSCULAR DISEASES
IL261878A (en) Treatment of skin conditions and diseases associated with microbial biofilms

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201014

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20211122

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 453/02 20060101ALI20211116BHEP

Ipc: A61K 31/444 20060101AFI20211116BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231003